ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
5.66
-0.17 (-2.91%)
Jul 30, 2026, 10:25 AM EDT - Market open
ARS Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 24.32 | 41.32 | 50.82 | 70.97 | 210.52 | 60.06 |
Short-Term Investments | 176.65 | 203.67 | 263.21 | 157.39 | 63.86 | - |
Cash & Short-Term Investments | 200.97 | 244.99 | 314.02 | 228.36 | 274.38 | 60.06 |
Cash Growth | -27.11% | -21.98% | 37.51% | -16.77% | 356.82% | -84.46% |
Accounts Receivable | 28.66 | 25.35 | 8.18 | - | - | - |
Inventory | 8.82 | 8.37 | 5.21 | - | - | - |
Other Current Assets | 6.79 | 6.19 | 6.89 | 3.37 | 3.32 | 0.67 |
Total Current Assets | 245.24 | 284.9 | 334.3 | 231.73 | 277.7 | 60.73 |
Net Property, Plant & Equipment | 2.29 | 2.47 | 1.07 | 0.82 | 0.77 | 0.69 |
Other Intangible Assets | 14.18 | 14.45 | 7.37 | - | - | - |
Other Long-Term Assets | 25.87 | 25.84 | 8.42 | 0.64 | 2.96 | 0.02 |
Total Assets | 287.57 | 327.65 | 351.15 | 233.19 | 281.44 | 61.45 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 48.26 | 37.95 | 22.84 | 2.15 | 4.93 | 3.11 |
Short-Term Debt | - | - | - | - | - | 3.48 |
Current Portion of Leases | 0.59 | 0.59 | 0.04 | 0.24 | 0.23 | 0.14 |
Unearned Revenue | 0.76 | 0.61 | 0.56 | - | 0.28 | 1.46 |
Total Current Liabilities | 49.61 | 39.15 | 23.44 | 2.39 | 5.44 | 8.19 |
Long-Term Debt | 96.52 | 96.37 | - | - | - | 4.93 |
Long-Term Leases | - | - | - | 0.04 | 0.25 | 0.48 |
Other Long-Term Liabilities | 80.13 | 77.88 | 70.92 | - | 2.85 | 3.08 |
Total Long-Term Liabilities | 176.65 | 174.25 | 70.92 | 0.04 | 3.11 | 8.49 |
Total Liabilities | 226.26 | 213.39 | 94.36 | 2.43 | 8.55 | 16.68 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
Additional Paid-in Capital | 416.62 | 408.73 | 379.87 | 362 | 349.41 | 10.98 |
Accumulated Other Comprehensive Income | -0.1 | 0.13 | 0.22 | 0.05 | 0.41 | - |
Retained Earnings | -355.22 | -294.6 | -123.31 | -131.3 | -76.94 | -42.26 |
Total Common Shareholders' Equity | 61.31 | 114.26 | 256.8 | 230.76 | 272.89 | -31.27 |
Minority Interest | - | - | - | - | - | 76.04 |
Shareholders' Equity | 61.31 | 114.26 | 256.8 | 230.76 | 272.89 | 44.77 |
Total Liabilities & Equity | 287.57 | 327.65 | 351.15 | 233.19 | 281.44 | 61.45 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 97.11 | 96.96 | 0.04 | 0.27 | 0.48 | 9.03 |
Net Cash (Debt) | 103.86 | 148.02 | 313.98 | 228.09 | 273.9 | 51.03 |
Net Cash Growth | -62.32% | -52.86% | 37.66% | -16.73% | 436.74% | -86.66% |
Net Cash Per Share | 1.05 | 1.50 | 3.07 | 2.40 | 6.86 | 1.77 |
Book Value | 61.31 | 114.26 | 256.8 | 230.76 | 272.89 | -31.27 |
Book Value Per Share | 0.62 | 1.16 | 2.51 | 2.42 | 6.83 | -1.08 |
Tangible Book Value | 47.13 | 99.81 | 249.43 | 230.76 | 272.89 | -31.27 |
Tangible Book Value Per Share | 0.48 | 1.01 | 2.44 | 2.42 | 6.83 | -1.08 |